CLINICAL TRIALS PROFILE FOR MYFEMBREE
✉ Email this page to a colleague
All Clinical Trials for MYFEMBREE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT04756037 ↗ | Study of the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are at Risk for Pregnancy | Recruiting | Myovant Sciences GmbH | Phase 3 | 2021-03-18 | The purpose of this study is to assess the contraceptive efficacy of relugolix combination therapy. |
| NCT05538689 ↗ | Surgical Myomectomy Followed by Oral Myfembree Versus Standard of Care Trial (SOUL) | Not yet recruiting | Myovant Sciences GmbH | Phase 4 | 2022-10-01 | In this project, the proposition is that the use of daily dosed Myfembree ( a combination of relugolix with estradiol and norethindrone acetate), FDA-approved medication to treat heavy menses fibroid-related symptoms, has the potential to delay the recurrence of fibroid symptoms, prolong the improved quality of life and delay the need for re-intervention after uterine sparing surgery versus the routine standard of care. |
| NCT05538689 ↗ | Surgical Myomectomy Followed by Oral Myfembree Versus Standard of Care Trial (SOUL) | Not yet recruiting | University of Chicago | Phase 4 | 2022-10-01 | In this project, the proposition is that the use of daily dosed Myfembree ( a combination of relugolix with estradiol and norethindrone acetate), FDA-approved medication to treat heavy menses fibroid-related symptoms, has the potential to delay the recurrence of fibroid symptoms, prolong the improved quality of life and delay the need for re-intervention after uterine sparing surgery versus the routine standard of care. |
| NCT05862272 ↗ | A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis | Not yet recruiting | Myovant Sciences GmbH | Phase 3 | 2023-05-01 | The purpose of this clinical trial to characterize changes in bone mineral density during continuous treatment with relugolix combination tablet for up to 48 months (4 years) and 1 year of post-treatment follow-up in premenopausal women with heavy menstrual bleeding associated with uterine leiomyomas (fibroids) or with moderate-to-severe pain associated with endometriosis. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for MYFEMBREE
Condition Name
Clinical Trial Locations for MYFEMBREE
Trials by Country
Clinical Trial Progress for MYFEMBREE
Clinical Trial Phase
Clinical Trial Sponsors for MYFEMBREE
Sponsor Name
